ES2159056T3 - Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco. - Google Patents

Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco.

Info

Publication number
ES2159056T3
ES2159056T3 ES96939709T ES96939709T ES2159056T3 ES 2159056 T3 ES2159056 T3 ES 2159056T3 ES 96939709 T ES96939709 T ES 96939709T ES 96939709 T ES96939709 T ES 96939709T ES 2159056 T3 ES2159056 T3 ES 2159056T3
Authority
ES
Spain
Prior art keywords
target molecule
biomolecules
magnetic resonance
nuclear magnetic
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96939709T
Other languages
English (en)
Other versions
ES2159056T5 (es
Inventor
Stephen W Fesik
Philip J Hajduk
Edward T Olejniczak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27415774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159056(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/558,633 external-priority patent/US5891643A/en
Priority claimed from US08/744,701 external-priority patent/US5989827A/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of ES2159056T3 publication Critical patent/ES2159056T3/es
Publication of ES2159056T5 publication Critical patent/ES2159056T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46—NMR spectroscopy
    • G01R33/4633—Sequences for multi-dimensional NMR
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION PROPORCIONA UN PROCESO DE DISEÑO DE COMPUESTOS QUE SE UNEN A MOLECULAS OBJETIVO ESPECIFICAS. EL PROCESO INCLUYE LOS SIGUIENTES PASOS: A) IDENTIFICACION DE UN PRIMER LIGANDO DE LA MOLECULA OBJETIVO UTILIZANDO ESPECTROSCOPIA BIDIMENSIONAL DE CORRELACION 15 N/ 1 H NMR; B) IDENTIFICACION DE UN SEGUNDO LIGANDO DE LA MOLECULA OBJETIVO UTILIZANDO ESPECTROSCOPIA BIDIMENSIONAL DE CORRELACION 15 N/ SUP ,1 H NMR; C) FORMACION DE UN COMPLEJO TERNARIO POR UNION DE LOS LIGANDOS PRIMERO Y SEGUNDO A LA MOLECULA OBJETIVO; D) DETERMINACION DE LA ESTRUCTURA TRIDIMENSIONAL DEL COMPLEJO TERNARIO Y DE ESTA FORMA DE LA ORIENTACION ESPACIAL DE LOS LIGANDOS PRIMERO Y SEGUNDO SOBRE LA MOLECULA OBJETIVO; Y E) UNION DE LOS LIGANDOS PRIMERO Y SEGUNDO PARA FORMAR EL FARMACO, EN EL QUE SE CONSERVA LA ORIENTACION ESPACIAL DEL PASO (D).
ES96939709T 1995-11-14 1996-11-13 Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco. Expired - Lifetime ES2159056T5 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/558,633 US5891643A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to design ligands to target biomolecules
US558633 1995-11-14
US67890396A 1996-07-12 1996-07-12
US678903 1996-07-12
US744701 1996-10-31
US08/744,701 US5989827A (en) 1995-11-14 1996-10-31 Use of nuclear magnetic resonance to design ligands to target biomolecules

Publications (2)

Publication Number Publication Date
ES2159056T3 true ES2159056T3 (es) 2001-09-16
ES2159056T5 ES2159056T5 (es) 2007-07-16

Family

ID=27415774

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96939709T Expired - Lifetime ES2159056T5 (es) 1995-11-14 1996-11-13 Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco.

Country Status (12)

Country Link
EP (1) EP0870197B2 (es)
JP (1) JP3300366B2 (es)
AT (1) ATE201768T1 (es)
AU (1) AU711092B2 (es)
DE (1) DE69613146T3 (es)
DK (1) DK0870197T4 (es)
ES (1) ES2159056T5 (es)
GR (1) GR3036454T3 (es)
IL (1) IL123572A (es)
MX (1) MX9803805A (es)
PT (1) PT870197E (es)
WO (1) WO1997018469A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US6344330B1 (en) 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
DE69933774D1 (de) * 1998-07-21 2006-12-07 Univ Rutgers Verbinden einer gensequenz mit einer genfunktion mittels dreidimensionaler (3d) proteinstrukturbestimmung
US6333149B1 (en) 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
BR0108606A (pt) * 2000-02-25 2003-01-07 Wyeth Corp Métodos de planejamento de droga com base na estrutura empregando-se em/rmn
JP5129424B2 (ja) 2000-09-27 2013-01-30 ユニヴェルシテイト レイデン リガンドの発見または薬物スクリーニング手段としてのｎｍｒ利用法
US7653490B2 (en) 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
NO20025738D0 (no) * 2002-11-29 2002-11-29 Amersham Health As Metode
JP4192078B2 (ja) 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
EP1715357A4 (en) * 2004-02-02 2009-09-16 Mitsubishi Chem Corp NMR SIGNAL ALLOCATION PROCESS
US20090239760A1 (en) 2006-03-14 2009-09-24 University Of Basel Method for the Identification of New Leads for Drug Candidates
KR20200057071A (ko) * 2017-09-25 2020-05-25 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557276A1 (en) * 1989-12-29 1993-09-01 University Technologies International Inc. (Uti) Methods for modelling tertiary structures of biologically active ligands including agonists and antagonists thereto and novel synthetic antagonists based on angiotensin
US5393669A (en) * 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US8558663B2 (en) † 2007-11-30 2013-10-15 Bank Of America Corporation Integration of facial recognition into cross channel authentication
DE102008042959A1 (de) † 2008-10-20 2010-04-22 Zf Friedrichshafen Ag Verfahren zur Steuerung eines Kraftfahrzeug-Antriebsstrangs
US8678903B1 (en) † 2012-09-13 2014-03-25 Chia-Yen Lin Mobile device having a virtual spin wheel and virtual spin wheel control method of the same

Also Published As

Publication number Publication date
WO1997018469A3 (en) 1997-08-07
ES2159056T5 (es) 2007-07-16
DE69613146T3 (de) 2007-06-14
DE69613146D1 (de) 2001-07-05
AU7680496A (en) 1997-06-05
EP0870197B1 (en) 2001-05-30
PT870197E (pt) 2001-11-30
ATE201768T1 (de) 2001-06-15
IL123572A0 (en) 1998-10-30
MX9803805A (es) 1998-09-30
EP0870197B2 (en) 2006-11-08
WO1997018469A2 (en) 1997-05-22
DK0870197T4 (da) 2007-02-26
EP0870197A2 (en) 1998-10-14
DK0870197T3 (da) 2001-08-27
GR3036454T3 (en) 2001-11-30
JP3300366B2 (ja) 2002-07-08
IL123572A (en) 2004-06-01
DE69613146T2 (de) 2003-01-16
AU711092B2 (en) 1999-10-07
JP2002510384A (ja) 2002-04-02

Similar Documents

Publication Publication Date Title
ES2143793T3 (es) Utilizacion de la resistencia magnetica nuclear para identificar ligandos con biomoleculas blanco.
ES2159056T3 (es) Utilizacion de la resonancia magnetica nuclear para diseñar ligandos que se unen a biomoleculas blanco.
CA2653517A1 (en) Process of designing a drug
CA2286795A1 (en) Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
ES2174075T3 (es) Librerias combinatorias de compuestos bioquimicos marcados y metodos para producir las mismas.
CY1109876T1 (el) Μεθοδοι για εκλεκτικη στοχευση
DE69526665D1 (de) Antigen bindende peptide (abtides) aus peptidbibliotheken
DE3883478D1 (de) Peridinin-Chlorophyll-Komplex als fluoreszierende Erkennungszeichen.
ATE216777T1 (de) Affinitäts-selektion von liganden mittels massenspektroskopie
JPH1025299A (ja) 整列ペプチド、及びそれを用いたタンパク質の結合・相互作用部位検出方法
DE60222816D1 (de) Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung
PT982314E (pt) Valeraldeido e processo para a sua preparacao
PT90265A (pt) Metodo rapido para analise de mutacoes
ATE314660T1 (de) Anwendung der 1h-nmr-doppelquantenspektroskopie zur identifizierung von liganden, die mit ziel- biomolekülen wechselwirken
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
Jafari The Assembly and Function of PWI Domain Containing Complexes and Poxvirus Proteins
GRIMES Metallacarborane-based precursors for electroactive materials(Final Report, 1 Jun. 1992- 31 May 1995)
CA2366488A1 (en) Optimization of ligand affinity for rna targets using mass spectrometry

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 870197

Country of ref document: ES